MACROGENICS INC (MGNX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
MGNX currently has 63.4M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 1.65% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 13, 2026 |
10-Q filing | 63.4M shares outstanding |
63M | 0 |
| Mar 09, 2026 |
10-K filing | 63.2M shares outstanding |
63M | 0 |
| Nov 12, 2025 |
10-Q filing | 63.3M shares outstanding |
63M | 0 |
| Aug 14, 2025 |
10-Q filing | 63.1M shares outstanding |
63M | 0 |
| May 13, 2025 |
10-Q filing | 63.0M shares outstanding |
63M | 0 |
| Mar 20, 2025 |
10-K filing | 62.6M shares outstanding |
63M | 0 |
| Nov 05, 2024 |
10-Q filing | 62.7M shares outstanding |
63M | 0 |
| Aug 06, 2024 |
10-Q filing | 62.7M shares outstanding |
63M | 0 |
| May 09, 2024 |
10-Q filing | 62.3M shares outstanding |
62M | 0 |
| Mar 07, 2024 |
10-K filing | 61.9M shares outstanding |
62M | 0 |
| Nov 06, 2023 |
10-Q filing | 62.0M shares outstanding |
62M | 0 |
| Nov 06, 2023 |
S-3 filing: The company is offering shares of its common stock with an aggregate offering price of up to $100,000,000 through an "at the market" offering made from time to time through its sales agent, Cowen. The company intends to use the net proceeds of this offering to fund research and development expenses for its clinical and preclinical pipeline, in-licensing or acquiring other products or technologies, and for other general corporate purposes, including working capital. |
62M | 0 |
| Aug 09, 2023 |
10-Q filing | 61.9M shares outstanding |
62M | 0 |
| May 09, 2023 |
10-Q filing | 61.8M shares outstanding |
62M | 0 |
| Mar 15, 2023 |
POS AM filing: The filing is a POS AM (Post-Effective Amendment) for MacroGenics, Inc., indicating the company may offer and sell up to $300,000,000 of common stock, preferred stock, or debt securities in one or more series. Additionally, they are offering shares of common stock having an aggregate offering price of up to $100,000,000 in an "at the market" offering through their sales agent, Cowen. |
61M | 0 |
| Mar 15, 2023 |
10-K filing | 61.4M shares outstanding |
61M | 27K |
| Nov 03, 2022 |
10-Q filing | 61.5M shares outstanding |
61M | 0 |
| Aug 08, 2022 |
10-Q filing | 61.4M shares outstanding |
61M | 0 |
| May 03, 2022 |
10-Q filing | 61.3M shares outstanding |
61M | 0 |
| Feb 24, 2022 |
10-K filing | 59.9M shares outstanding |
60M | 0 |
| Nov 02, 2021 |
10-Q filing | 61.2M shares outstanding |
61M | 0 |
| Jul 29, 2021 |
10-Q filing | 60.1M shares outstanding |
60M | 0 |
| Jun 16, 2021 |
8-K filing: MacroGenics, Inc. entered into a stock purchase agreement with Zai Lab US LLC to issue and sell 958,467 shares of common stock at a price of $31.30 per share, for aggregate gross proceeds of approximately $30 million, in a private placement. ($30.0M proceeds) |
60M | 0 |
| Apr 29, 2021 |
10-Q filing | 60.0M shares outstanding |
60M | 0 |
| Feb 25, 2021 |
10-K filing | 56.3M shares outstanding |
56M | 0 |
| Nov 04, 2020 |
10-Q filing | 56.2M shares outstanding |
56M | 0 |
| Jul 31, 2020 |
10-Q filing | 54.1M shares outstanding |
54M | 0 |
| Jun 19, 2020 |
8-K filing: MacroGenics, Inc. increased the amount of common stock that can be sold through Cowen and Company, LLC, as agent, from an aggregate offering price of up to $50.0 million to an aggregate offering price of up to $175.0 million, and as of the date of this report, the Company has sold 2,269,745 Shares, representing $50.0 million in gross proceeds before any discounts and fees, under the Sales Agreement. ($50.0M proceeds) |
49M | 0 |
| May 05, 2020 |
10-Q filing | 49.1M shares outstanding |
49M | 0 |
| Feb 25, 2020 |
10-K filing | 49.0M shares outstanding |
49M | 0 |